- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01307917
Flavonoids in the Treatment of Endothelial Dysfunction in Children With Diabetes (flavonoid)
Endothelial Dysfunction and the Role of Flavonoids in the Prevention of Nephropathy Among Pediatric Patients With Diabetes
Diabetes is the most common metabolic disease of childhood. Vascular disease is a leading complication of diabetes, and attempts to maintain close glycemic control do not prevent the sequelae that claim the lives and quality of life of millions of diabetics each year. Up to forty percent of patients with diabetes mellitus ultimately develop diabetic nephropathy, the most common cause of end-stage renal disease requiring dialysis in the US. Flavonoid-rich diets are a promising intervention to prevent the endothelial dysfunction that apparently leads to this deadly complication. The mechanisms are still unclear but probably involve nitric oxide synthesis. The investigators hypothesize that early maintenance of the integrity of renal vasculature will significantly improve the lifelong prognosis for patients with diabetes. Flavonoids with anti-inflammatory and antioxidant activities could be used to protect endothelial function, and together with good glycemic control, prevent the development and progression of nephropathy. The investigators aims are to:
- compare endothelial function by studying reactive hyperemia, nitric oxide, and proinflammatory factors in adolescents (12-21 years old) with diabetes versus healthy sex- and age-matched control subjects.
- identify early markers in urine for vascular endothelial injury.
- examine the effects of flavonoids on vascular function, urine nitric oxide, and proinflammatory factors in patients with diabetes mellitus.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Amarillo, Texas, United States, 79106
- Texas Tech University Health Sciences Center School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adolescents 12 - 21 years old
- with T1DM or T2DM and their healthy age- and sex-matched peers
- DM subjects must maintain good glycemic control with HbA1C < 11
Exclusion Criteria:
- no co-morbidities that could lead to inflammation or decline in renal function will be allowed
- no non-steroidal anti-inflammatory drugs should be taken, for any reason, within 48 hours prior to the study days
- no smoking will be permitted on the day of Pre-Study Evaluation or Study Days 0, 14, or 21
- controls should not be taking any medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: healthy controls high flavonoid
20 healthy adolescents (12-21 years old) receiving the flavonoid-rich capsule/supplement
|
for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
|
Active Comparator: healthy controls low flavonoid
20 healthy adolescents (12-21 years old) receiving the placebo
|
for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
|
Experimental: T1DM or T2DM high flavonoid
20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the capsule/supplement
|
for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
|
Active Comparator: T1DM or T2DM low flavonoid
20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the placebo
|
for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
compare endothelial function by studying reactive hyperemia, nitric oxide, and proinflammatory factors in adolescents (12-21 years old) with diabetes vs. healthy sex- and age-matched control subjects.
Time Frame: day 0; day 14; day 21
|
day 0; day 14; day 21
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
identify early markers in urine for vascular endothelial injury
Time Frame: screening, day 0, day 14, day 21
|
screening, day 0, day 14, day 21
|
examine the effects of flavonoids on vascular function, urine nitric oxide, and proinflammatory factors in patients with diabetes mellitus
Time Frame: day 0, day 14, day 21
|
day 0, day 14, day 21
|
Collaborators and Investigators
Investigators
- Principal Investigator: Tetyana Vasylyeva, MD, PhD, Texas Tech University Health Sciences Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A09-3502
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Nephropathy
-
Zheng GuoNot yet recruitingDiabetic Nephropathy Type 2
-
The Third Xiangya Hospital of Central South UniversityCompletedType 2 Diabetic NephropathyChina
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownDiabetic Nephropathy Type 2Mexico
-
Assiut UniversityUnknownDiabetic Nephropathy Type 2
-
University of Sao Paulo General HospitalCompleted
-
Second Affiliated Hospital, School of Medicine,...Second Affiliated Hospital of Wenzhou Medical University; Lishui Country People...RecruitingDiabetic Nephropathy Type 2 | BiomarkerChina
-
Assiut UniversityNot yet recruitingType 2 DM é Diabetic Nephropathy
-
Chinese PLA General HospitalCompletedInsulin Pump Therapy in Treating Diabetic Nephropathy
-
PfizerTerminatedType 2 Diabetic NephropathyUnited States
-
Chang Gung Memorial HospitalUnknown
Clinical Trials on flavonoids
-
National Polytechnic Institute, MexicoCompletedFrail Elderly Syndrome | Sarcopenia
-
Instituto Nacional de Perinatologia Isidro Espinosa...National Polytechnic Institute, MexicoNot yet recruitingMetabolic SyndromeMexico
-
Utah State UniversityCompletedInflammation | Metabolic Syndrome XUnited States
-
Guillermo Ceballos ReyesInstituto de Seguridad y Servicios Sociales de los Trabajadores del EstadoRecruitingFatigue Syndrome, Chronic | Long Covid19Mexico
-
Capital Medical UniversityXinjiang Uygur Pharmaceutical Co., Ltd.RecruitingAlzheimer DiseaseChina
-
PharmanexUtah State UniversityCompletedHealthyUnited States
-
Xinjiang Uygur Pharmaceutical Co., Ltd.Chinese Academy of SciencesUnknown
-
Quadram Institute BioscienceEuropean UnionCompleted
-
Giellepi S.p.AOpera CRO, a TIGERMED Group CompanyNot yet recruiting
-
Beni-Suef UniversityCompletedMetabolic Syndrome and Diabetic NeuropathyEgypt